Compare LWAY & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | ARMP |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 383.7M |
| IPO Year | 1995 | 1996 |
| Metric | LWAY | ARMP |
|---|---|---|
| Price | $19.37 | $9.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $15.00 |
| AVG Volume (30 Days) | 28.3K | ★ 40.2K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.40 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $27.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.00 | $0.90 |
| 52 Week High | $34.20 | $13.75 |
| Indicator | LWAY | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 22.64 | 50.10 |
| Support Level | N/A | $5.14 |
| Resistance Level | $22.80 | $12.11 |
| Average True Range (ATR) | 0.71 | 0.96 |
| MACD | -0.18 | -0.27 |
| Stochastic Oscillator | 2.29 | 17.65 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.